Evaluation of oral tegafur‐uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non‐distant metastatic TNM stage IV nasopharyngeal carcinoma

The study was aimed to evaluate the impact of accumulated oral tegafur‐uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease‐free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non‐distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC).

[1]  F. Sung,et al.  Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan , 2015, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[2]  D. Waxman,et al.  Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. , 2015, Cancer letters.

[3]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[4]  Y. Shih,et al.  Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. , 2014, International journal of radiation oncology, biology, physics.

[5]  G. Capellá,et al.  Metronomic chemotherapy following the maximum tolerated dose is an effective anti‐tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells , 2013, International journal of cancer.

[6]  Chih-Hung Hsu,et al.  Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma , 2012, Oncology.

[7]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[8]  Qing Liu,et al.  The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials , 2010, BMC Cancer.

[9]  Chih-Hung Hsu,et al.  Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. , 2010, Journal of Hepatology.

[10]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Joaquim Bellmunt,et al.  Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). , 2010, The Lancet. Oncology.

[12]  Jin-Ching Lin,et al.  Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma , 2010, Clinical Cancer Research.

[13]  R. McLendon,et al.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study , 2009, British Journal of Cancer.

[14]  L. Landi,et al.  Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer , 2009, Clinical Cancer Research.

[15]  H. Iwata,et al.  Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[17]  C. Tiu,et al.  Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer , 2007, Cancer Chemotherapy and Pharmacology.

[18]  K. Shirouzu,et al.  Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. , 2007, Anticancer research.

[19]  V. Khoo,et al.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. , 2007, The Journal of urology.

[20]  H. Adami,et al.  The Enigmatic Epidemiology of Nasopharyngeal Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[21]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[22]  S. Leung,et al.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. , 2005, International journal of radiation oncology, biology, physics.

[23]  Jin-Ching Lin,et al.  Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? , 2004, International journal of radiation oncology, biology, physics.

[24]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[25]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[26]  S. Leung,et al.  Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.

[27]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[28]  S. Leung,et al.  Plasma Cell‐free Epstein‐Barr Virus DNA Quantitation in Patients with Nasopharyngeal Carcinoma: Correlation with Clinical Staging , 2000, Annals of the New York Academy of Sciences.

[29]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Jin-Ching Lin,et al.  Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. , 2017, Oral oncology.

[31]  G. Klement,et al.  Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? , 2011, Journal of pediatric hematology/oncology.

[32]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.